TEMPLE CITY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Fulgent Genetics has applied to list its common stock on the NASDAQ Global Market under “FLGT”.

Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. are serving as joint book-running managers for the proposed offering. Raymond James & Associates, Inc. will act as lead manager for the proposed offering and BTIG will act as co-manager.

The offering will be made only by means of a prospectus. A copy of the prospectus relating to this offering, when available, may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at +1-800-221-1037, or by email at newyork.prospectus@credit-suisse.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Suite 800, Minneapolis, MN 55402, by telephone at +1-800-747-3924, or by email to prospectus@pjc.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.